EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity

Leonie Müller-Jensen iD, Axel R Schulz iD, Henrik E Mei iD, Raphael Mohr iD, Claas Ulrich iD, Philipp Knape iD, Nikolaj Frost iD, Stefan Frischbutter iD, Desiree Kunkel iD, Christian Schinke iD, Lorena Ginesta Roque, Smilla K Maierhof iD und 6 weitere

Neuro-Oncology · 02.02.2024 · 26 (2) · 279-294

DOI: 10.1093/neuonc/noad198 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neuro-Oncology, online erschienen am 12.10.2023. Verfasst von Leonie Müller-Jensen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-…. Hauptthemen laut MEDLINE: Lung Neoplasms, Melanoma. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft, Berlin Institute of Health, German Centre for Cardiovascular Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neurologic immune-related adverse events (irAE-n) are rare but severe toxicities of immune checkpoint inhibitor (ICI) treatment. To overcome diagnostic and therapeutic challenges, a better mechanistic understanding of irAE-n is paramount.

Methods

In this observational cohort study, we collected serum and peripheral blood samples from 34 consecutive cancer patients with irAE-n (during acute illness) and 49 cancer control patients without irAE-n (pre- and on-ICI treatment, n = 44 without high-grade irAEs, n = 5 with high-grade nonneurologic irAEs). Patients received either anti-programmed cell death protein (PD)-1 or anti-PD ligand-1 monotherapy or anti-PD-1/anti-cytotoxic T-lymphocyte-associated protein-4 combination therapy. Most common cancers were melanoma, lung cancer, and hepatocellular carcinoma. Peripheral blood immune profiling was performed using 48-marker single-cell mass cytometry and a multiplex cytokine assay.

Results

During acute illness, patients with irAE-n presented higher frequencies of cluster of differentiation (CD)8+ effector memory type (EM-)1 and central memory (CM) T cells compared to controls without irAEs. Multiorgan immunotoxicities (neurologic + nonneurologic) were associated with higher CD8+ EM1 T cell counts. While there were no B cell changes in the overall cohort, we detected a marked decrease of IgD− CD11c+ CD21low and IgD− CD24+ CD21high B cells in a subgroup of patients with autoantibody-positive irAE-n. We further identified signatures indicative of enhanced chemotaxis and inflammation in irAE-n patients and discovered C-X-C motif chemokine ligand (CXCL)10 as a promising marker to diagnose high-grade immunotoxicities such as irAE-n.

Conclusions

We demonstrate profound and partly subgroup-specific immune cell dysregulation in irAE-n patients, which may guide future biomarker development and targeted treatment approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsMelanomaHumansAcute DiseaseAutoimmunityLigandsRetrospective Studies

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmune-related adverse eventsimmunotherapymass cytometryneurotoxicity

Substanzen

Ligands

Autor:innen und Institutionen

  • Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.
  • Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Mass Cytometry Laboratory, German Rheumatism Research Center (DRFZ), A Leibniz Institute, Berlin, Germany.
  • Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Dermatology, Venerology, and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Collegium Medicum Berlin GmbH, Berlin, Germany.

ORCID-Profile: Leonie Müller-Jensen, Axel R Schulz, Henrik E Mei, Raphael Mohr, Claas Ulrich, Philipp Knape, Nikolaj Frost, Stefan Frischbutter, Desiree Kunkel, Christian Schinke, Smilla K Maierhof, Lucie Heinzerling, Matthias Endres, Wolfgang Boehmerle, Petra Huehnchen, Samuel Knauss

Förderung

  • Deutsche Forschungsgemeinschaft
  • Berlin Institute of Health
  • German Centre for Cardiovascular Research
  • German Federal Ministry of Education and Research
  • Else-Kröner-Fresenius-Stiftung
  • Charité - Universitätsmedizin Berlin
  • AnimalfreeResearch Switzerland
  • SenUMVK Berlin

Zitieren

APA

Müller-Jensen, L., Schulz, A. R., Mei, H. E., Mohr, R., Ulrich, C., Knape, P., Frost, N., Frischbutter, S., Kunkel, D., Schinke, C., Ginesta Roque, L., Maierhof, S. K., Nickel, F. T., Heinzerling, L., Endres, M., Boehmerle, W., Huehnchen, P., & Knauss, S. (2024). Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity. Neuro-Oncology, 26(2), 279-294. https://doi.org/10.1093/neuonc/noad198

Vancouver

Müller-Jensen L, Schulz AR, Mei HE, Mohr R, Ulrich C, Knape P, et al. Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity. Neuro-Oncology. 2024;26(2):279-294. doi:10.1093/neuonc/noad198

BibTeX
@article{MllerJensen2024,
  author = {Müller-Jensen, Leonie and Schulz, Axel R and Mei, Henrik E and Mohr, Raphael and Ulrich, Claas and Knape, Philipp and Frost, Nikolaj and Frischbutter, Stefan and Kunkel, Desiree and Schinke, Christian and Ginesta Roque, Lorena and Maierhof, Smilla K and Nickel, Florian T and Heinzerling, Lucie and Endres, Matthias and Boehmerle, Wolfgang and Huehnchen, Petra and Knauss, Samuel},
  title = {Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {2},
  pages = {279--294},
  doi = {10.1093/neuonc/noad198}
}
Kostenlos starten →